VANCOUVER, June 19, 2017 /CNW/ - Isodiol International
Inc. (CSE: ISOL) (OTC: LAGBF) (Frankfurt: LB6A.F) (the "Company" or "Isodiol") a global cannabis innovator specializing in
the development of pharmaceutical and consumer products is pleased to announce it has initiated the drug approval process through
the Brazilian Health Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade cannabidiol (CBD) products for
placement in the Special Category List for approved imported CBD products.
As a part of the ANVISA approval process, the Company is also proud to announce physicians are currently prescribing the
Isoderm product. "We are extremely excited to have officially entered the South American market for our pharmaceutical grade
products," said Marcos Agramont, Chief Executive Officer of Isodiol Inc.
"We anticipate receiving full approval within the next quarter, which allows us time to develop and implement our
commercialization strategy for the Brazilian market. We will continue to develop products and sale channels in North America for our Nutraceutical products however, as the global CBD market evolves, we want to ensure
Isodiol is at the forefront of this movement. As leaders in the domestic space, we will ensure Isodiol has a significant presence
in the implementation of global standards with health authorities and government officials in turning this CBD movement into a
legitimate industry," said Marcos.
The company has also signed a non-binding letter of intent for an exclusive partnership agreement with an established
Brazilian based pharmaceutical importer and distributor, who will provide the following services,
- Obtain formal ANVISA approval for the products in Brazil,
- Work exclusively with Isodiol for the importation, promotion, development and sale of products,
- Sponsor events for physicians, distributors and pharmaceutical companies to spread awareness, educate and promote
products.
Additional information will be provided around the financial terms of the partnership agreement in the coming weeks.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in
manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for
Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest
quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and
acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into
Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
"Marcos Agramont"
CEO & Director
Join Us On Face Book:
https://www.facebook.com/isodiol/
Twitter: @isodiol
Forward-Looking Information: This news release contains "forward-looking information"
within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the
Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations
reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be
correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are
subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those
contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from
those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required
by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward
looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE Isodiol International Inc.
View original content: http://www.newswire.ca/en/releases/archive/June2017/19/c7335.html